Evidence map›Paper›PMID 34774518›Full record

ArticleThe American journal of pathology2022

Inhibition of Vascular Endothelial Growth Factor Receptors 1 and 2 Attenuates Natural Killer Cell and Innate Immune Responses in an Experimental Model for Obliterative Bronchiolitis.

Rainer Krebs, Jussi M Tikkanen, Alireza Raissadati, Maria Hollmén, Kishor Dhaygude, Karl B Lemström

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rainer KrebsTranslational Immunology Research Program, Transplantation Laboratory, University of Helsinki, Helsinki, Finland. Electronic address: rainer.krebs@helsinki.fi.
Jussi M TikkanenTranslational Immunology Research Program, Transplantation Laboratory, University of Helsinki, Helsinki, Finland; Department of Cardiothoracic Surgery, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Alireza RaissadatiTranslational Immunology Research Program, Transplantation Laboratory, University of Helsinki, Helsinki, Finland.
Maria HollménTranslational Immunology Research Program, Transplantation Laboratory, University of Helsinki, Helsinki, Finland.
Kishor DhaygudeTranslational Immunology Research Program, Transplantation Laboratory, University of Helsinki, Helsinki, Finland.
Karl B LemströmTranslational Immunology Research Program, Transplantation Laboratory, University of Helsinki, Helsinki, Finland; Department of Cardiothoracic Surgery, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obliterative bronchiolitis (OB) after lung transplantation is a nonreversible, life-threatening complication. Herein, the role of vascular endothelial growth factor receptor (Vegfr)-1 and -2 was investigated in the development of obliterative airway disease (OAD), an experimental model for OB. The nonimmunosuppressed recipients underwent transplantation with fully major histocompatibility complex mismatched heterotopic tracheal allografts and received Vegfr1 and -2-specific monoclonal antibodies either alone or in combination, or rat IgG as a control. The treatment with Vegfr1- or -2-blocking antibody significantly decreased intragraft mRNA expression of natural killer cell activation markers early after transplantation. This was followed by reduced infiltration of Cd11b

Indexed as

Immunity, InnateLung TransplantationAnimalsBronchiolitis ObliteransCalcineurinKiller Cells, NaturalMaleMiceMice, Inbred BALB CRatsSignal TransductionVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2CalcineurinKdr protein, mouseVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2

Identifiers

PMID34774518
PMCPMC12178338
OpenAlexW3214393941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.